FollowMyHealth Patient Portal

David Michael Holtzman, MD

Andrew B. and Gretchen P. Jones Professor of Neurology
Charlotte and Paul Hagemann Professor of Neurology
Chairman, Department of Neurology
Professor, Molecular Biology and Pharmacology
Neurologist-in-Chief, Barnes-Jewish Hospital

Specialty Areas

Neurology - Adult
Memory Disorders and Diagnosis
Alzheimer's Disease
Dementia

Board Certifications

Neurology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Neurology, molecular biology, pharmacology, nervous system, Alzheimer's disease, memory, brain research, cerebral blood flow, metabolism, neuroscience, lipid research, neuron, mental retardation, Down's syndrome, neonatal hypoxic-ischemia, brain disorders, spinal fluid.

  • Maps & Directions
  • Education
  • Publication & Research
  • Financial Disclosures

Maps & Directions

Maps & Directions

Center for Advanced Medicine
Memory Diagnostic Center

4921 Parkview Place
St. Louis, MO 63110

Suite: C
Floor: 6
Office Phone: (314) 286-1967
Fax: (314) 286-1985
Email: holtzman@neuro.wustl.edu

Education

Education

Residency: Neurology, University of California, San Francisco, California 1989
Medical Degree: Northwestern University, Chicago, Illinois 1985
BS: Science in Medical Education, Northwestern University, Chicago, Illinois 1983

Publication & Research

Publication & Research

Lumbar Cerebrospinal Fluid Biomarkers of Posthemorrhagic Hydrocephalus of Prematurity: Amyloid Precursor Protein, Soluble Amyloid Precursor Protein α, and L1 Cell Adhesion Molecule.
Morales DM, Silver SA, Morgan CD, Mercer D, Inder TE, Holtzman DM, Wallendorf MJ, Rao R, McAllister JP, Limbrick DD Jr
Neurosurgery. 2016 Aug 26;

PMID:
    27571524
    [PubMed - as supplied by publisher]
Related citations


Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes.
Chung WS, Verghese PB, Chakraborty C, Joung J, Hyman BT, Ulrich JD, Holtzman DM, Barres BA
Proc Natl Acad Sci U S A. 2016 Sep 6; 113(36)10186-91. doi: 10.1073/pnas.1609896113.

PMID:
    27559087
    [PubMed - in process]
Related citations


Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
Gordon BA, Blazey T, Su Y, Fagan AM, Holtzman DM, Morris JC, Benzinger TL
JAMA Neurol. 2016 Aug 22; doi: 10.1001/jamaneurol.2016.2642.

PMID:
    27548756
    [PubMed - as supplied by publisher]
Related citations


Nmnat1 protects neuronal function without altering phospho-tau pathology in a mouse model of tauopathy.
Musiek ES, Xiong DD, Patel T, Sasaki Y, Wang Y, Bauer AQ, Singh R, Finn SL, Culver JP, Milbrandt J, Holtzman DM
Ann Clin Transl Neurol. 2016 Jun; 3(6)434-42. doi: 10.1002/acn3.308.

PMID:
    27547771
    [PubMed]
Related citations


BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.
Lim YY, Hassenstab J, Cruchaga C, Goate A, Fagan AM, Benzinger TL, Maruff P, Snyder PJ, Masters CL, Allegri R, Chhatwal J, Farlow MR, Graff-Radford NR, Laske C, Levin J, McDade E, Ringman JM, Rossor M, Salloway S, Schofield PR, Holtzman DM, Morris JC, Bateman RJ, Dominantly Inherited Alzheimer Network
Brain. 2016 Aug 12; pii: aww200.

PMID:
    27521573
    [PubMed - as supplied by publisher]
Related citations


Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease.
Minter MR, Zhang C, Leone V, Ringus DL, Zhang X, Oyler-Castrillo P, Musch MW, Liao F, Ward JF, Holtzman DM, Chang EB, Tanzi RE, Sisodia SS
Sci Rep. 2016 Jul 21; 630028. doi: 10.1038/srep30028.

PMID:
    27443609
    [PubMed - in process]
Related citations


Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence?
Stanley M, Macauley SL, Holtzman DM
J Exp Med. 2016 Jul 25; 213(8)1375-85. doi: 10.1084/jem.20160493.

PMID:
    27432942
    [PubMed - in process]
Related citations


Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels.
Babulal GM, Ghoshal N, Head D, Vernon EK, Holtzman DM, Benzinger TL, Fagan AM, Morris JC, Roe CM
Am J Geriatr Psychiatry. 2016 Apr 19; pii: S1064-7481(16)30082-3. doi: 10.1016/j.jagp.2016.04.004.

PMID:
    27426238
    [PubMed - as supplied by publisher]
Related citations


Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.
Vlassenko AG, McCue L, Jasielec MS, Su Y, Gordon BA, Xiong C, Holtzman DM, Benzinger TL, Morris JC, Fagan AM
Ann Neurol. 2016 Sep; 80(3)379-87. doi: 10.1002/ana.24719.

PMID:
    27398953
    [PubMed - in process]
Related citations


Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models.
Zhao L, Gottesdiener AJ, Parmar M, Li M, Kaminsky SM, Chiuchiolo MJ, Sondhi D, Sullivan PM, Holtzman DM, Crystal RG, Paul SM
Neurobiol Aging. 2016 Aug; 44159-72. doi: 10.1016/j.neurobiolaging.2016.04.020.

PMID:
    27318144
    [PubMed - in process]
Related citations


NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers.
Vos SJ, Gordon BA, Su Y, Visser PJ, Holtzman DM, Morris JC, Fagan AM, Benzinger TL
Neurobiol Aging. 2016 Aug; 441-8. doi: 10.1016/j.neurobiolaging.2016.03.025.

PMID:
    27318129
    [PubMed - in process]
Related citations


The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging.
Gordon BA, Friedrichsen K, Brier M, Blazey T, Su Y, Christensen J, Aldea P, McConathy J, Holtzman DM, Cairns NJ, Morris JC, Fagan AM, Ances BM, Benzinger TL
Brain. 2016 Aug; 139(Pt 8)2249-60. doi: 10.1093/brain/aww139.

PMID:
    27286736
    [PubMed - in process]
Related citations


Comparison of a single-channel EEG sleep study to polysomnography.
Lucey BP, Mcleland JS, Toedebusch CD, Boyd J, Morris JC, Landsness EC, Yamada K, Holtzman DM
J Sleep Res. 2016 Jun 2; doi: 10.1111/jsr.12417.

PMID:
    27252090
    [PubMed - as supplied by publisher]
Related citations


Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease.
Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, Owen C, Aldea P, Su Y, Hassenstab J, Cairns NJ, Holtzman DM, Fagan AM, Morris JC, Benzinger TL, Ances BM
Sci Transl Med. 2016 May 11; 8(338)338ra66. doi: 10.1126/scitranslmed.aaf2362.

PMID:
    27169802
    [PubMed - in process]
Related citations


Tau: From research to clinical development.
Holtzman DM, Carrillo MC, Hendrix JA, Bain LJ, Catafau AM, Gault LM, Goedert M, Mandelkow E, Mandelkow EM, Miller DS, Ostrowitzki S, Polydoro M, Smith S, Wittmann M, Hutton M
Alzheimers Dement. 2016 May 4; pii: S1552-5260(16)30019-X. doi: 10.1016/j.jalz.2016.03.018.

PMID:
    27154059
    [PubMed - as supplied by publisher]
Related citations


Obstructive sleep apnea decreases central nervous system-derived proteins in the cerebrospinal fluid.
Ju YE, Finn MB, Sutphen CL, Herries EM, Jerome GM, Ladenson JH, Crimmins DL, Fagan AM, Holtzman DM
Ann Neurol. 2016 Jul; 80(1)154-9. doi: 10.1002/ana.24672.

PMID:
    27129429
    [PubMed - in process]
Related citations


Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals.
Roe CM, Barco PP, Head DM, Ghoshal N, Selsor N, Babulal GM, Fierberg R, Vernon EK, Shulman N, Johnson A, Fague S, Xiong C, Grant EA, Campbell A, Ott BR, Holtzman DM, Benzinger TL, Fagan AM, Carr DB, Morris JC
Alzheimer Dis Assoc Disord. 2016 Apr 28;

PMID:
    27128959
    [PubMed - as supplied by publisher]
Related citations


Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease.
Ingber AP, Hassenstab J, Fagan AM, Benzinger TL, Grant EA, Holtzman DM, Morris JC, Roe CM
J Alzheimers Dis. 2016; 52(3)1055-64. doi: 10.3233/JAD-150478.

PMID:
    27104893
    [PubMed - in process]
Related citations


TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques.
Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, Cella M, Grutzendler J, DeMattos RB, Cirrito JR, Holtzman DM, Colonna M
J Exp Med. 2016 May 2; 213(5)667-75. doi: 10.1084/jem.20151948.

PMID:
    27091843
    [PubMed - in process]
Related citations


Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer's disease.
Liu CC, Zhao N, Yamaguchi Y, Cirrito JR, Kanekiyo T, Holtzman DM, Bu G
Sci Transl Med. 2016 Mar 30; 8(332)332ra44. doi: 10.1126/scitranslmed.aad3650.

PMID:
    27030596
    [PubMed - in process]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following earned financial interests during calendar year 2015.

Company Name: C2N Diagnostics

Royalties: > $200,000

Equity: Yes

Consulting/Advisory Board: $10,001 - $25,000

Speaker Fees:

Reporting Date: May 01, 2016


Company Name: Neurophage

Royalties:

Equity: No

Consulting/Advisory Board: $10,001 - $25,000

Speaker Fees:

Reporting Date: May 01, 2016

Areas of Research Interest

Underlying mechanisms that lead to Alzheimer's disease.